Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bolaget.

Datum Källa Rubrik Typ Alternativ
2023-01-27 ChemoTech Scandinavian ChemoTech publishes clinical strategy update from Medical Director Dr. Suhail Mufti Pressreleaser Ladda ner | Visa Stäng
2023-01-27 ChemoTech Scandinavian ChemoTech publicerar klinisk strategiuppdatering från Medical Director Dr Suhail Mufti Pressreleaser Ladda ner | Visa Stäng
2023-01-24 ChemoTech ChemoTech: TSE-behandlingar vid Royal Veterinary College visar mycket lovande resultat Pressreleaser Ladda ner | Visa Stäng
2023-01-24 ChemoTech ChemoTech: TSE treatments at the Royal Veterinary College shows very promising results Pressreleaser Ladda ner | Visa Stäng
2023-01-20 ChemoTech Scandinavian ChemoTech's Medical Director presents clinical strategy Pressreleaser Ladda ner | Visa Stäng
2023-01-20 ChemoTech Scandinavian ChemoTechs Medical Director presenterar klinisk strategi Pressreleaser Ladda ner | Visa Stäng
2023-01-18 ChemoTech Scandinavian ChemoTech presenterar på Redeye Fight Cancer Day Pressreleaser Ladda ner | Visa Stäng
2023-01-18 ChemoTech Scandinavian ChemoTech presents at Redeye Fight Cancer Day Pressreleaser Ladda ner | Visa Stäng
2023-01-17 ChemoTech ChemoTech: Pancreatic cancer patients in Ukraine treated with Tumour Specific Electroporation™ (TSE) are continuing to improve Pressreleaser Ladda ner | Visa Stäng
2023-01-17 ChemoTech ChemoTech: Bukspottkörtelcancerpatienter i Ukraina som behandlats med Tumörspecific Elektroporation™ (TSE) fortsätter att förbättras Pressreleaser Ladda ner | Visa Stäng
2022-12-21 ChemoTech ChemoTech: TSE-behandlingar utfördes på tre hästar utan generell anestesi vid Royal Veterinary College i London Pressreleaser Ladda ner | Visa Stäng
2022-12-21 ChemoTech ChemoTech: TSE treatments were performed on three horses without general anaesthesia at the Royal Veterinary College in London Pressreleaser Ladda ner | Visa Stäng
2022-12-20 ChemoTech Scandinavian ChemoTech publicerar vd-intervju Pressreleaser Visa Stäng
2022-11-29 ChemoTech Scandinavian ChemoTech changes Certified Adviser till Redeye AB Pressreleaser Ladda ner | Visa Stäng
2022-11-29 ChemoTech Scandinavian ChemoTech byter Certified Adviser till Redeye AB Pressreleaser Ladda ner | Visa Stäng
2022-11-28 ChemoTech Scandinavian ChemoTechs Animal Care-division tecknar betydande kliniskt utvärderingsavtal med The Royal Veterinary College Pressreleaser Ladda ner | Visa Stäng
2022-11-28 ChemoTech Scandinavian ChemoTech's Animal Care division signs significant Clinical Evaluation Agreement with The Royal Veterinary College Pressreleaser Ladda ner | Visa Stäng
2022-11-22 ChemoTech Scandinavian ChemoTech AB publicerar delårsrapport för januari-september 2022 Rapporter Ladda ner | Visa Stäng
2022-11-17 ChemoTech ChemoTech: Important update regarding cancer patients treated with IQwave™ Tumour Specific Electroporation™ (TSE) at Ulis Hospital Ukraine Pressreleaser Ladda ner | Visa Stäng
2022-11-17 ChemoTech ChemoTech: Viktig uppdatering angående cancerpatienter som behandlats med IQwave™ Tumörspecifik Elektroporation™ (TSE) på Ulis Hospital i Ukraina Pressreleaser Ladda ner | Visa Stäng
2022-10-26 ChemoTech Scandinavian ChemoTech AB offentliggör utfall i företrädesemission Pressreleaser Ladda ner | Visa Stäng
2022-10-26 ChemoTech Scandinavian ChemoTech AB announces outcome in rights issue Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 26 Oct 2022 | Scandinavian Chemotech

Scandinavian ChemoTech AB announces outcome in rights issue

”The fact that, despite the current financial climate, we were able to attract so many people to subscribe to the issue is very gratifying. With this funding, we get the opportunity to continue the commercialization within both Animal and Human Care, while at the same time giving room for continued clinical studies. It is now of the utmost importance that we continue to collect clinical data and experience with TSE as a treatment option and at the same time study the immunotherapeutic effects that we create. We see potential for significant commercial success together with our current and new distributors in the near term and focus on delivering on the business opportunities that lie ahead. Our financial strategy is to extend/replace existing credits or find alternative solutions. Creating continued value for global cancer care as well as for our new and existing shareholders is of the highest priority.” says Mohan Frick, CEO Scandinavian ChemoTech AB.   

The subscription period in the Rights Issue ended on October 21, 2022. The outcome shows that a total of 2,384,449 units have been subscribed for through the Rights Issue and the Company will thus receive approximately SEK 14.9 million before issue costs, of which approximately SEK 0.7 million through offset of loans. Upon full exercise of all warrants of series TO3, the Company may be provided with an additional capital injection of up to approximately SEK 29.8 million after the exercise period that runs from and including April 11, 2023, up to and including April 24, 2023.

Allotment of units subscribed for without the support of unit rights has taken place in accordance with what is stated in the prospectus that the Company published on September 29, 2022, due to the Rights Issue (the ”Prospectus”). Notification of such allotment is announced separately through settlement notes. Nominee-registered shareholders receive notification of allotment in accordance with instructions from the respective nominee.

Through the Rights Issue, the number of shares in the Company increase by 2,384,449 shares, divided on 328,333 A-shares and 2,056,116 B-shares, from 9,629,055 shares, divided on 1050 000 A-shares and 8579 055 B-shares to 12,013,504 shares, divided on 1,378,333 A-shares and 10,635,171 B-shares. The share capital will increase with SEK 1,192,224.50, from SEK 4,814,527.50 to SEK 6,006,752.00. If all warrants of series TO3A and TO3B are fully exercised for subscription of new shares in the Company, the number of shares in the Company will increase with an additional 2,384,449 shares, divided on 328,333 A-shares and 2,056,116 B-shares, from 12,013,504 shares, divided on 1,378,333 A-shares and 10,635,171 B-shares to 14,397,953 shares, divided on 1,706,666 A-shares and 12,691,287 B-shares. The share capital will increase with an additional SEK 1,192,224.50, from SEK 6,006,752.00 to SEK 7,198,976.50. Each warrant of series TO3A entitles the holder to subscribe for one (1) new A-share in the Company. Each warrant of series TO3B entitles the holder to subscribe for one (1) new B-share in the Company. The subscription price for shares supported by the warrants of series TO3A and TO3B amounts to seventy (70) percent of the volume-weighted average price (VWAP) of the Company’s B-share on Nasdaq First North Growth Market during the period from and including March 23, 2023, up to and including April 5, 2023, however a minimum of the share’s quota value and a maximum of SEK 12.50 per share.

Trading with BTU (Paid Subscribed Unit) takes place on Nasdaq First North Growth Market until the conversion of BTU into shares and warrants after the Rights Issue has been registered with the Swedish Companies Registration Office. Registration with the Swedish Companies Registration Office is expected to take place during week 44, 2022. Trading in the new B-shares and warrants of series TO3B are expected to commence on Nasdaq First North Premier Growth Market on or about November 16, 2022.

Full terms and conditions for the warrants of series TO3A and TO3B are available on the Company’s website, www.chemotech.se

Advisors

Mangold Fondkommission AB is the financial advisor to ChemoTech in connection with the Rights Issue. Moll Wendén Advokatbyrå is the legal advisor to ChemoTech in connection to the Rights Issue.

For more information, please contact:

Mohan Frick, CEO

Tel: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Certified Adviser: Erik Penser Bank, Tel: Corporate Finance AB, Tel: +46 8-463 80 00,

E-mail:certifiedadviser@penser.se

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 26 October 2022 21:00 CET.

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech’s shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company’s Certified Adviser. Read more at: www.chemotech.se.

Important Information

Release, announcement or distribution of this press release may, in certain jurisdictions, be subjectto restrictions according to law and people in those jurisdictions, in which this press release has beenannounced or distributed, should inform themselves of and follow such legal restrictions. This pressrelease does not constitute an offer, or a solicitation of any offer, to buy or subscribe for anysecurities in ChemoTech in any jurisdiction. Invitation to the persons concerned to participate in the RightsIssue will only take place through the EU growth prospectus which the Company intends to publishin connection with the Rights Issue.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribefor securities in the United States. The securities referred to herein may not be sold in the UnitedStates absent registration or an exemption from registration under the US Securities Act of 1933, asamended. The information in this press release may not be announced, published or distributed, directly or indirectly, in whole or in part, inor into the United States, Australia, Hong Kong, Japan, Canada, New Zealand,Switzerland, South Africa, South Korea or in any other jurisdiction where the announcement, publication ordistribution of the information would not comply with applicable laws and regulations.

Within the European Economic Area, no offer is made to the public of securities in any country otherthan Sweden. In other Member States of the European Union, such an offer may only be made inaccordance with the exceptions in the Prospectus Regulation (EU) 2017/1129.

This press release contains certain forward-looking information that reflects the Company’s presentview of future events as well as financial and operational development. Words such as ”intend”,”assess”, ”expect”, ”may”, ”plan”, ”believe”, ”estimate” and other expressions entailing indicationsor predictions of future development or trends, not based on historical facts, constitute forward-lookinginformation. Forward-looking information is inherently associated with both known andunknown risks and uncertainties as it depends on future events and circumstances. Forward-lookinginformation is not a guarantee of future results or development and actual outcomes may differmaterially from the statements set forth in the forward-looking information.

2022-10-20 ChemoTech Scandinavian ChemoTech AB publishes supplementary prospectus Pressreleaser Ladda ner | Visa Stäng
2022-10-20 ChemoTech Scandinavian ChemoTech AB offentliggör tilläggsprospekt Pressreleaser Ladda ner | Visa Stäng
2022-10-19 ChemoTech Handel med uniträtter i Scandinavian ChemoTechs pågående emission förlängs Pressreleaser Ladda ner | Visa Stäng
2022-10-19 ChemoTech Trading of unit rights in Scandinavian ChemoTech's ongoing issue is extended Pressreleaser Ladda ner | Visa Stäng
2022-10-19 ChemoTech (RETRANS) ChemoTech's Animal Care division signs Letter of Intent with a prominent player in the North American veterinary market Pressreleaser Ladda ner | Visa Stäng
2022-10-19 ChemoTech (OMS) ChemoTechs Animal Care-division tecknar Letter of Intent med en framstående aktör på den nordamerikanska veterinärmarknaden Pressreleaser Ladda ner | Visa Stäng
2022-10-18 ChemoTech ChemoTech's Animal Care division signs Letter of Intent with a prominent player in the North American veterinary market Pressreleaser Ladda ner | Visa Stäng
2022-10-18 ChemoTech ChemoTechs Animal Care-division tecknar Letter of Intent med en framstående aktör på den nordamerikanska veterinärmarknaden Pressreleaser Ladda ner | Visa Stäng
2022-10-18 ChemoTech Scandinavian ChemoTech's Animal Care division signs exclusive distribution agreement for the Australian and New Zealand market Pressreleaser Ladda ner | Visa Stäng
2022-10-18 ChemoTech Scandinavian ChemoTechs Animal Care-division tecknar exklusivt distributionsavtal för den australiensiska och nyzeeländska marknaden Pressreleaser Ladda ner | Visa Stäng
2022-10-17 ChemoTech Scandinavian ChemoTechs Animal Care-division får order från FloridaWild Veterinary Hospital Pressreleaser Ladda ner | Visa Stäng
2022-10-17 ChemoTech Scandinavian ChemoTech's Animal Care division receives purchase order from FloridaWild Veterinary Hospital Pressreleaser Ladda ner | Visa Stäng
2022-10-13 ChemoTech Board members of Scandinavian ChemoTech fully subscribe to the current issue Pressreleaser Ladda ner | Visa Stäng
2022-10-13 ChemoTech Styrelsemedlemmar i Scandinavian ChemoTech tecknar fullt i pågående emission Pressreleaser Ladda ner | Visa Stäng
2022-10-06 ChemoTech Scandinavian ChemoTech utökar sin ledningsgrupp med ytterligare klinisk kompetens Pressreleaser Ladda ner | Visa Stäng
2022-10-06 ChemoTech Scandinavian ChemoTech expands its management team with further clinical competency Pressreleaser Ladda ner | Visa Stäng
2022-10-03 ChemoTech Scandinavian ChemoTech och India-Sweden Healthcare Innovation Centre firar starten av den kliniska studien på AIIMS Jodhpur Pressreleaser Ladda ner | Visa Stäng
2022-10-03 ChemoTech Scandinavian ChemoTech and the India-Sweden Healthcare Innovation Centre celebrate the start of the clinical trial at AIIMS Jodhpur Pressreleaser Ladda ner | Visa Stäng
2022-09-29 ChemoTech Scandinavian ChemoTech announces postponement of the quarterly report Pressreleaser Ladda ner | Visa Stäng
2022-09-29 ChemoTech Scandinavian ChemoTech meddelar senareläggning av kvartalsrapporten Pressreleaser Ladda ner | Visa Stäng
2022-09-29 ChemoTech Scandinavian ChemoTech offentliggör prospekt med anledning av företrädesemission av units Pressreleaser Ladda ner | Visa Stäng
2022-09-29 ChemoTech Scandinavian ChemoTech publishes prospectus due to rights issue of units Pressreleaser Ladda ner | Visa Stäng
2022-09-28 ChemoTech ChemoTech: Rättelse: Svensk indiske affärsmannen Prashant Agarwal deltar i emissionen som toppgarant Pressreleaser Ladda ner | Visa Stäng
2022-09-28 ChemoTech ChemoTech: Correction: Swedish Indian businessman Prashant Agarwal participates in the share issue as top underwriter Pressreleaser Ladda ner | Visa Stäng
2022-09-23 ChemoTech ChemoTech: Swedish Indian businessman Prashant Agarwal participates in the share issue as top underwriter Pressreleaser Ladda ner | Visa Stäng
2022-09-23 ChemoTech ChemoTech: Svensk indiske affärsmannen Prashant Agarwal deltar i emissionen som toppgarant Pressreleaser Ladda ner | Visa Stäng
2022-09-23 ChemoTech ChemoTech: Bukspottskörtelscancerpatient i Ukraina utskriven efter TSE behandling Pressreleaser Ladda ner | Visa Stäng
2022-09-23 ChemoTech ChemoTech: Pancreatic cancer patient in Ukraine discharged after TSE treatment Pressreleaser Ladda ner | Visa Stäng
2022-09-21 ChemoTech ChemoTech: The Board of Directors resolves on a rights issue of units of approximately SEK 20.1 million Pressreleaser Ladda ner | Visa Stäng
2022-09-21 ChemoTech ChemoTech: Styrelsen beslutar om företrädesemission av units om cirka 20,1 MSEK Pressreleaser Ladda ner | Visa Stäng
2022-09-18 ChemoTech Scandinavian ChemoTechs IQwave™ används för att behandla bukspottkörtelcancer på Ulis sjukhus i Ukraina Pressreleaser Ladda ner | Visa Stäng
2022-09-18 ChemoTech Scandinavian ChemoTech's IQwave™ used to treat pancreatic cancer at Ulis hospital in Ukraine Pressreleaser Ladda ner | Visa Stäng
2022-09-18 ChemoTech Scandinavian ChemoTech's IQwave™ used as first-line treatment with great clinical outcome in Ukraine Pressreleaser Ladda ner | Visa Stäng
2022-09-18 ChemoTech Scandinavian ChemoTechs IQwave™ används som förstahandsbehandling med positivt kliniskt resultat i Ukraina Pressreleaser Ladda ner | Visa Stäng
2022-09-15 ChemoTech ChemoTech: En publicerad fallserie studie indikerar att TSE kan utföras utan generell anestesi Pressreleaser Ladda ner | Visa Stäng
2022-09-15 ChemoTech ChemoTech: A published case series study indicates that TSE can be performed without general anaesthesia Pressreleaser Ladda ner | Visa Stäng
2022-09-05 ChemoTech ChemoTech: TSE-behandling av två hundar på veterinärsjukhuset FloridaWild visar på lovande resultat Pressreleaser Ladda ner | Visa Stäng
2022-09-05 ChemoTech ChemoTech: TSE treatment of two dogs at FloridaWild veterinary hospital shows promising results Pressreleaser Ladda ner | Visa Stäng
2022-09-01 ChemoTech Scandinavian ChemoTech welcomes new energy to its management Pressreleaser Ladda ner | Visa Stäng
2022-09-01 ChemoTech Scandinavian ChemoTech välkomnar ny kraft till ledningen Pressreleaser Ladda ner | Visa Stäng
2022-08-31 ChemoTech Scandinavian ChemoTech's subsidiary Vetiqure AB receives a first order from Hasvet Medikal AS Pressreleaser Ladda ner | Visa Stäng
2022-08-31 ChemoTech Scandinavian ChemoTechs dotterbolag Vetiqure AB erhåller en första order från Hasvet Medikal AS Pressreleaser Ladda ner | Visa Stäng
2022-08-30 ChemoTech Scandinavian ChemoTechs dotterbolag Vetiqure AB skriver exklusivt distributörsavtal för Turkiet med Hasvet Medikal AS Pressreleaser Ladda ner | Visa Stäng
2022-08-30 ChemoTech Scandinavian ChemoTech's subsidiary Vetiqure AB signs an exclusive distributor agreement for Turkey with Hasvet Medikal AS Pressreleaser Ladda ner | Visa Stäng
2022-08-26 ChemoTech Scandinavian ChemoTech's subsidiary Vetiqure AB signs agreement with a German AniCura clinic for participation in a study Pressreleaser Ladda ner | Visa Stäng
2022-08-26 ChemoTech Scandinavian ChemoTechs dotterbolag Vetiqure AB skriver avtal med tysk AniCura-klinik för deltagande i studie Pressreleaser Ladda ner | Visa Stäng
2022-08-16 ChemoTech Scandinavian ChemoTech AB (publ) Interim report Q2 January - June 2022 - Executive Summary Pressreleaser Ladda ner | Visa Stäng
2022-08-16 ChemoTech Scandinavian ChemoTech AB publicerar delårsrapport för januari-juni 2022 Rapporter Ladda ner | Visa Stäng
2022-08-16 ChemoTech Scandinavian ChemoTech strengthens finances by raising a loan of 2.5 MSEK from board and CEO Pressreleaser Ladda ner | Visa Stäng
2022-08-16 ChemoTech Scandinavian ChemoTech stärker finanserna genom att ta upp lån på 2,5 MSEK från styrelse och VD Pressreleaser Ladda ner | Visa Stäng
2022-08-10 ChemoTech ChemoTech: Scandinavian ChemTech får positivt utfall i FloridaWilds utvärdering av vetIQure[TM] Pressreleaser Ladda ner | Visa Stäng
2022-08-10 ChemoTech Scandinavian ChemoTech reaching a positive outcome in FloridaWild's evaluation of vetIQure[™] Pressreleaser Ladda ner | Visa Stäng
2022-07-26 Kalqyl Kalqyl: Initial take: ChemoTech Analyser Ladda ner | Visa Stäng
2022-07-26 ChemoTech Kalqyl publish initial take analysis on Scandinavian ChemoTech Pressreleaser Ladda ner | Visa Stäng
2022-07-26 ChemoTech Kalqyl publicerar uppdragsanalys på Scandinavian ChemoTech Pressreleaser Ladda ner | Visa Stäng
2022-07-20 ChemoTech Scandinavian ChemoTech announces that TSE™ therapy has been initiated at Ulis Medical Centre in Ukraine Pressreleaser Ladda ner | Visa Stäng
2022-07-20 ChemoTech Scandinavian ChemoTech meddelar att TSE™-behandling har inletts vid Ulis Medical Center i Ukraina Pressreleaser Ladda ner | Visa Stäng
2022-07-13 ChemoTech Scandinavian ChemoTech håller den första utbildningen på Ulis Medical Centre i Ukraina Pressreleaser Ladda ner | Visa Stäng
2022-07-13 ChemoTech Scandinavian ChemoTech holds the first training session at Ulis Medical Centre in Ukraine Pressreleaser Ladda ner | Visa Stäng
2022-07-13 ChemoTech Scandinavian ChemoTech announces the receival of ethics committee approval for a clinical trial with the TSE™ technology at `All India Institute of Medical Sciences' (AIIMS) in India Pressreleaser Ladda ner | Visa Stäng
2022-07-13 ChemoTech Scandinavian ChemoTech tillkännager mottagandet av etiskt godkännande för en studie med TSE™-teknologin vid 'All India Institute of Medical Sciences' (AIIMS) i Indien Pressreleaser Ladda ner | Visa Stäng
2022-06-23 ChemoTech Scandinavian ChemoTech ger en lägesrapport och önskar alla en trevlig midsommar och semester Pressreleaser Ladda ner | Visa Stäng
2022-06-23 ChemoTech Scandinavian ChemoTech provides a status report and wishes everyone a pleasant midsummer and holiday Pressreleaser Ladda ner | Visa Stäng
2022-06-21 ChemoTech Scandinavian ChemoTech anlitar IR-konsult Pressreleaser Ladda ner | Visa Stäng
2022-06-21 ChemoTech Scandinavian ChemoTech hires investor relations consultant Pressreleaser Ladda ner | Visa Stäng
2022-06-16 ChemoTech Scandinavian ChemoTech tecknar avtal med Kalqyl om uppdragsanalys Pressreleaser Ladda ner | Visa Stäng
2022-06-16 ChemoTech Scandinavian ChemoTech signs agreement with Kalqyl on assignment analysis Pressreleaser Ladda ner | Visa Stäng
2022-06-03 ChemoTech Scandinavian ChemoTech receives a new patent on the Japanese market Pressreleaser Ladda ner | Visa Stäng
2022-06-03 ChemoTech Scandinavian ChemoTech erhåller nytt patent på den japanska marknaden Pressreleaser Ladda ner | Visa Stäng
2022-05-31 ChemoTech Scandinavian ChemoTech's dotterbolag summerar ett mycket lyckat deltagande på ESVONC Pressreleaser Ladda ner | Visa Stäng
2022-05-31 ChemoTech Scandinavian ChemoTech's subsidiary sums up a very successful participation at ESVONC Pressreleaser Ladda ner | Visa Stäng
2022-05-26 ChemoTech Scandinavian ChemoTechs TSE teknologi ger hopp till hästar som lider av Sarcoider Pressreleaser Ladda ner | Visa Stäng
2022-05-26 ChemoTech Scandinavian ChemoTech's TSE technology gives hope to horses suffering from sarcoids Pressreleaser Ladda ner | Visa Stäng
2022-05-24 ChemoTech Kommuniké från årsstämma i Scandinavian ChemoTech AB (publ) den 24 maj 2022 Pressreleaser Ladda ner | Visa Stäng
2022-05-17 ChemoTech Pressmeddelande Lund 17 maj 2022 Scandinavian ChemoTech erhåller slutligt patentgodkännande i EU för den tumörspecifika kontrollenheten i vår TSE™-plattform Pressreleaser Ladda ner | Visa Stäng
2022-05-17 ChemoTech Press release Lund 17 May 2022 Scandinavian ChemoTech receives final patent approval in the EU for the tumour specific control unit in our TSE™ platform Pressreleaser Ladda ner | Visa Stäng
2022-05-16 ChemoTech Scandinavian ChemoTechs dotterbolag Vetiqure deltar vid ESVONCs kongress i Italien Pressreleaser Ladda ner | Visa Stäng
2022-05-16 ChemoTech Scandinavian ChemoTech's subsidiary Vetiqure participates in ESVONC's congress in Italy Pressreleaser Ladda ner | Visa Stäng
2022-05-09 ChemoTech ChemoTech supports a Ukrainian hospital by selling an IQwave™ at a discounted price Pressreleaser Ladda ner | Visa Stäng
2022-05-09 ChemoTech ChemoTech stödjer ett ukrainskt sjukhus genom att sälja en IQwave™ till rabatterat pris Pressreleaser Ladda ner | Visa Stäng
2022-05-03 ChemoTech Scandinavian ChemoTech gästar Småbolagspodden Pressreleaser Ladda ner | Visa Stäng
2022-05-03 ChemoTech Scandinavian ChemoTech publicerar 2021 års årsredovisning Pressreleaser Visa Stäng
2022-05-03 ChemoTech Scandinavian ChemoTech AB publicerar delårsrapport för januari-mars 2022 Rapporter Ladda ner | Visa Stäng
2022-04-21 ChemoTech Kallelse till årsstämma i Scandinavian ChemoTech AB Pressreleaser Ladda ner | Visa Stäng
2022-04-12 ChemoTech Scandinavian ChemoTech AB nominerade till Swecare Export Awards Pressreleaser Ladda ner | Visa Stäng
2022-04-12 ChemoTech Scandinavian ChemoTech AB nominated for the Swecare Export Awards Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

7 Mar 2023 | Bokslutskommuniké 2022